Meeting
2020 ASCO Virtual Scientific Program
Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC).
Authors
Ranju Kunwor
Thomas Jefferson University Hospital, Philadelphia, PA
Ranju Kunwor , Ramkaji Baniya , Maysa M. Abu-Khalaf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1060)
DOI
10.1200/JCO.2020.38.15_suppl.1060
Abstract #
1060
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.
First Author: Nusrat Jahan
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel
Poster
2023 ASCO Annual Meeting
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
First Author: Joseph J Zhao
Poster
2019 ASCO Annual Meeting
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).
First Author: Seth Andrew Wander